Q4 2023 Earnings Summary
- Reduction in contract labor expenses is expected to increase EBITDA in 2024. The company anticipates a decrease of approximately $60 million in contract labor expenses year-over-year, with about half of that amount positively impacting EBITDA. There is also potential for further reductions beyond this estimate.
- Margin improvement programs and initiatives provide potential upside not fully reflected in guidance. Management is highly focused on margin improvement and has disciplined initiatives in place. Many of these initiatives are not fully baked into the 2024 guidance, offering potential for better-than-expected performance.
- Potential divestitures could generate up to $1 billion in proceeds for deleveraging or accretive acquisitions. The company is evaluating inbound interest for divestitures that may make strategic sense, which could yield more than $1 billion. These proceeds could be used to pay down debt or invest in EBITDA-accretive opportunities, strengthening the company's capital structure.
- Increasing Medical Malpractice Expenses: The company noted that the malpractice environment is becoming more difficult, with higher settlements and jury awards than historically seen. They increased their self-insurance reserves for medical malpractice during the quarter, which suggests rising costs. This trend may continue to pressure margins if it persists.
- Payer Mix Shift Towards Medicare Advantage: The business experienced disproportionate growth in Medicare Advantage volumes compared to commercial volumes. Medicare Advantage outpaced commercial growth by about 2:1 in Q4 and 3:1 for the full year, which negatively affects net revenue per adjusted admission due to lower reimbursement rates from Medicare Advantage plans.
- High Leverage and Cash Flow Constraints: The company's net debt to adjusted EBITDA ratio is high at 7.88x. Additionally, cash flow from operations was impacted by increases in accounts receivable due to delayed payments and billing issues, including a $130 million headwind in Q4. This high leverage and cash flow challenges could limit financial flexibility.
-
Margin Improvement Drivers
Q: What are the key drivers of margin improvement implied for 2024?
A: Kevin explained that they expect 2% to 3% volume growth and favorable rate increases: 4% to 6% on commercial rates and 2.5% to 3% on Medicare ( ). They also anticipate reductions in contract labor expenses and some normalization of payer mix trends ( ). Additionally, they have a margin improvement program with various initiatives that could provide upside potential, though not all are baked into the guidance ( ). -
Divestiture Plans and Capital Deployment
Q: Are the divestiture plans strategic, and how will you deploy the potential $1 billion in proceeds?
A: Kevin stated that the potential divestitures result from inbound interest, and they are evaluating markets where it makes strategic sense to transact ( ). The proceeds could be used to delever the company by paying down debt or by growing EBITDA through acquisitions, depending on the market conditions at the time ( ). -
Cash Flow Shortfall and 2024 Guidance
Q: Can you provide more detail on the cash flow shortfall in Q4 and guidance for 2024?
A: Kevin attributed the Q4 cash flow shortfall to timing issues, including a $130 million headwind from increased accounts receivable, accelerated interest payments due to refinancing, and a $30 million legal settlement ( ). For 2024, they anticipate these issues to be resolved and did not include potential positives like 163(j) interest deductibility rollback or a tax refund in their guidance ( ). -
Medicare Advantage Pricing Yield
Q: Are you anticipating any offsets to the lower pricing yield from Medicare Advantage compared to fee-for-service Medicare?
A: Kevin acknowledged the yield differential due to downgrades and denials but expects some benefit in 2024 from new CMS guidance on the Two-Midnight Rule and prior authorization requirements ( ). They have also invested in clinical resources and a physician adviser program to support admitting physicians and improve realization rates ( ). -
Payer Mix Dynamics
Q: How do you view payer mix trends, and is there upside risk from exchange growth or commercial demand?
A: Kevin noted that while they grew both commercial and Medicare populations in Q4, Medicare Advantage volumes outpaced commercial by about 2:1 in Q4 and 3:1 for the full year ( ). They expect some moderation but remain cautious about payer mix dynamics in 2024 ( ). -
CapEx Plans and Flexibility
Q: Can you parse out the $350–$400 million in 2024 CapEx and its flexibility?
A: Kevin stated that CapEx will be split roughly 50% maintenance and 50% growth, with large projects winding down and fewer hospitals due to divestitures reducing maintenance needs ( ). Tim added that they are deliberate in capital allocation, focusing on outpatient growth, and could adjust spending based on opportunities and market conditions ( ). -
Medical Malpractice Reserves
Q: Why did you decide not to adjust out the med mal reserves from adjusted results, and are you comfortable with current reserve levels?
A: Kevin explained they left the reserves in adjusted EBITDA to avoid appearing selective in adjustments, especially with unexpected positives like the Mississippi program ( ). While the malpractice environment is challenging due to higher settlements, they expect expenses to normalize and highlighted their 89% reduction in serious safety events, which should reduce future claims ( ). -
Accounts Receivable Improvement
Q: Should we expect progress on accounts receivable improvement in Q1, or will it be gradual?
A: Kevin anticipates early benefits in Q1 from collecting the Mississippi supplemental program funds, with further improvements over the course of the year as they recapture built-up AR and manage payers ( ). -
Volume Growth Expectations
Q: Does the strong volume growth in 2023 create a comp issue for 2024, and how do you frame the volume outlook?
A: Kevin expects 2% to 3% volume growth in 2024, lower than in 2023 but still strong. They believe in their ability to grow volumes in their markets and have factored this into their 4% same-store revenue growth guidance ( ). -
Wage Inflation and Contract Labor
Q: What are your views on nurse wage inflation and contract labor utilization in guidance?
A: Kevin stated they are estimating 4% wage inflation for 2024, similar to 2023, but are exiting 2023 at a rate below that. Contract labor is expected to reduce, potentially providing up to $60 million in savings year-over-year, with about half flowing through to EBITDA ( ).